Kyntra Bio, Inc. Common Stock – Quartalsabschluss (NASDAQ:KYNB)

Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik

Vierteljährlich Jährlich

Market Capitalization 29.26 M
Employee 34
Founded 1993
CEO N/A
Website www.kyntrabio.com
Headquarter California, United States
FIGI BBG000FW5ZL6
Industry Technology

Gesamtumsatz

Jahresüberschuss

Unverwässertes Ergebnis je Aktie (Unverwässertes EPS)

Gesamtverschuldung

Freier Cashflow

Zahlungsmittel und Zahlungsmitteläquivalente

29.26 M Marktkapitalisierung

Kyntra Bio Inc

Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate. On January 8, 2026, FibroGen changed its name to Kyntra Bio and ticker symbol to KYNB.